References

Obesity and weight management in HIV: epidemiology, complications, and emerging treatments

10.1007/s11904-026-00776-1 · 2026 · External reference

Antiretrovirals and weight change: weighing the evidence

10.1093/cid/ciae191 · 2024 · External reference

The obesity transition: stages of the global epidemic

10.1016/s2213-8587(19)30026-9 · 2019 · External reference

An overview on the nutrition transition and its health implications: the Bellagio meeting

10.1079/phn2001280 · 2002 · External reference

Obesity is South Africa's new HIV epidemic

10.7196/samj.2024.v114i3.1927 · 2024 · External reference

Obesity management in adults: a review

10.1001/jama.2023.19897 · 2023 · External reference

Definition and diagnostic criteria of clinical obesity

10.1016/s2213-8587(24)00316-4 · 2025 · External reference

Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV

10.1111/hiv.13211 · 2022 · External reference

Dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate: Real-world assessment of effectiveness and weight Gain in naive people living with HIV of Asian OrigiN (DRAGON)

10.1016/j.ijid.2025.108321 · 2026 · External reference

Weight gain after antiretroviral therapy initiation and subsequent risk of metabolic and cardiovascular disease

10.1093/cid/ciad545 · 2024 · External reference

Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE

10.1016/s2352-3018(25)00354-6 · 2026 · External reference

Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV

10.1097/coh.0000000000000833 · 2024 · External reference

Final 192-week efficacy and safety results of the ADVANCE Trial, comparing 3 first-line antiretroviral regimens

10.1093/ofid/ofae007 · 2024 · External reference

Durability of the efficacy and safety of dolutegravir-based and low-dose efavirenz-based regimens for the initial treatment of human immunodeficiency virus type 1 infection in Cameroon: Week 192 data of the NAMSAL-ANRS-12313 Study

10.1093/ofid/ofad582 · 2023 · External reference

Weight gain during the dolutegravir transition in the African Cohort Study

10.1002/jia2.25899 · 2022 · External reference

Initial HIV therapy for adults and treatment-associated weight gain: the Opti-DOR Randomized Clinical Trial

10.1001/jama.2026.14762 · 2026 · External reference

Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration

10.1016/s2352-3018(24)00183-8 · 2024 · External reference

Untangling the causal ties between antiretrovirals and obesity

10.1016/s2352-3018(24)00214-5 · 2024 · External reference

Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: an observational study

10.1111/hiv.13638 · 2024 · External reference

Body weight and blood pressure changes on dolutegravir-, efavirenz- or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study

10.1002/jia2.26216 · 2024 · External reference

Incidence and determinants of excessive weight gain in people living with HIV initiating tenofovir, lamivudine, and dolutegravir-based therapy: a multicenter retrospective study in northwest Ethiopia

10.3389/fphar.2025.1394458 · 2025 · External reference

Initiation of dolutegravir vs efavirenz on 12- and 24-month weight, body mass index, blood pressure, and incident hypertension: a target trial emulation

10.1016/j.annepidem.2026.110074 · 2026 · External reference

Regional variation in weight change after the transition to dolutegravir in Uganda and South Africa

10.1097/qad.0000000000003888 · 2024 · External reference

A 48-week, randomized controlled trial of doravirine for individuals with HIV and obesity on integrase inhibitors and tenofovir alafenamide: the do it study (ACTG A5391)

10.1093/cid/ciag196 · 2026 · External reference

Trends in body mass index in the predolutegravir period in South Africa

10.4102/sajhivmed.v25i1.1523 · 2024 · External reference

Association between transitioning to a dolutegravir-based regimen and risk of incident hypertension in adults with HIV in West Africa: a multicentre target trial emulation study

10.1016/j.eclinm.2025.103584 · 2025 · External reference

Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda

10.1186/s12981-024-00615-6 · 2024 · External reference

Hypertension among people living with HIV receiving dolutegravir-based antiretroviral therapy in Ethiopia: a cross-sectional study

10.1038/s41598-025-06145-z · 2025 · External reference

Metabolic causes of liver disease among adults living with HIV from low- and middle-income countries: a cross-sectional study

10.1002/jia2.26238 · 2024 · External reference

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

10.1097/hep.0000000000000004 · 2023 · External reference

Nonalcoholic fatty liver disease in Africa: a hidden danger

10.1017/gheg.2019.2 · 2019 · External reference

Steatotic liver disease in people with HIV at Tshepong Hospital: a postmortem analysis

10.4102/sajhivmed.v25i1.1638 · 2024 · External reference

Metabolic dysfunction-associated steatotic liver disease in Asia: epidemiology, clinical features, and management

10.1016/j.cld.2026.01.010 · 2026 · External reference

Efficacy and acceptability of liraglutide for obesity in people with HIV: results of an open-label clinical trial in South Africa

10.1093/cid/ciag337 · 2026 · External reference

Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial

10.1016/s2213-8587(24)00150-5 · 2024 · External reference

Semaglutide improves markers of cardiovascular risk in people with HIV

10.1097/qad.0000000000004538 · 2026 · External reference

Weight loss associated with semaglutide treatment among people with HIV

10.1097/qad.0000000000003791 · 2024 · External reference

Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa

10.1002/jia2.26268 · 2024 · External reference

Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial

10.1016/s2352-3018(26)00036-6 · 2026 · External reference

Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment

10.1002/oby.23725 · 2023 · External reference

GLP-1 receptor agonists and the path to sustainable obesity care

10.1001/jamainternmed.2024.3579 · 2025 · External reference

Treatment with GLP-1 drugs must not replace obesity prevention in low and middle income countries

10.1136/bmj.s407 · 2026 · External reference